Physician profile
Amos C Johnson
NPI 1801805270
$3,722.67
in general payments reported to CMS, 2019-2025
15 companies · $647 in 2025
The $647 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $501 · 2021: $731 · 2022: $501 · 2023: $617 · 2024: $89.73 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,353.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $824.95 | 2019-2023 | Fasenra |
| Amgen INC. | $788.72 | 2020-2025 | Repatha, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $482.13 | 2022-2025 | |
| Lilly USA, LLC | $458.62 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $244.83 | 2021 | |
| Novo Nordisk INC | $238.56 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $189.26 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $156.03 | 2023-2025 | Edarbi, Azmiro, Edarbi |
| Abbvie INC. | $155.98 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.05 | 2021-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $52.05 | 2021-2022 | |
| Dexcom, INC. | $32.39 | 2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $16.18 | 2021 | |
| Phadia US INC. | $15.70 | 2020 | |
| Allergan, INC. | $11.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amos Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.